Navigation Links
Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in Zerenex™ (Ferric Citrate) Phase 3 Long-Term Study
Date:9/19/2011

NEW YORK, Sept. 19, 2011 /PRNewswire/ -- Keryx Biopharmaceuticals (Nasdaq: KERX) today announced completion of patient enrollment in the long-term study component of its Phase 3 registration program of Zerenex™, the Company's ferric iron-based phosphate binder for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in patients with end-stage renal disease (ESRD) on dialysis. The Zerenex Phase 3 registration program, which is being conducted pursuant to a Special Protocol Assessment (SPA) with the Food and Drug Administration (FDA), is comprised of an already successfully-completed Phase 3 short-term study, and this ongoing Phase 3 long-term study.    

This Phase 3 long-term study is a multicenter, randomized, open-label, safety and efficacy clinical trial in over 400 ESRD patients on hemodialysis or peritoneal dialysis. The study consists of a 2-week washout period followed by a 52-week safety assessment in which patients are randomized 2:1 to receive either Zerenex or an active control. The 52-week safety assessment period is followed by a 4-week efficacy assessment.  During the 4-week efficacy assessment, only those patients randomized to treatment with Zerenex during the safety assessment period will be randomized in a 1:1 ratio to either continue treatment with Zerenex or to be switched to placebo for a 4-week period.

Dr. Julia Lewis, Professor of Medicine, Department of Nephrology, Vanderbilt University School of Medicine, and member of the Executive Committee of the Collaborative Study Group, is the Study Chair of the Zerenex Phase 3 registration program. Dr. Samuel S. Blumenthal, Professor of Medicine at Medical College of Wisconsin, is the study's Co-Principal Investigator.

Ron Bentsur, Chief Executive Officer of Keryx, commented, "We are pleased to have completed patient enrollment into the Zerenex Phase 3 long
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in KRX-0401 (Perifosine) Phase 3 Refractory Advanced Colorectal Cancer Study
2. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2011 Financial Results
3. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2011 Financial Results
4. Keryx Biopharmaceuticals Announces Positive Final Data from Zerenex™ Short-Term Phase 3 Study
5. Keryx Biopharmaceuticals to Present at 13th Annual BIO CEO and Investor Conference
6. Keryx Biopharmaceuticals to Present at 29th Annual J.P. Morgan Healthcare Conference
7. Keryx Biopharmaceuticals to Present at Lazard Capital Markets 7th Annual Healthcare Conference
8. Keryx Biopharmaceuticals to Present at the UBS 2010 Global Life Sciences Conference
9. Æterna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Perifosine (KRX-0401) in the Treatment of Patients with Refractory Metastatic Colorectal Cancer
10. Æterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstroms Macroglobulinemia
11. Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... 15, 2014 Zymo Research Corp., has announced ... for safe ambient temperature storage and transport of ... infectivity of agents in such samples is completely ... of the viral nucleic acids for subsequent analyses.  ... epidemic in West Africa ...
(Date:9/15/2014)... September 2014 Die zweite jährliche ... 12. bis 18. Oktober stattfinden. Die IPAW ist ... Association (PPTA) und ihrer Mitgliedsunternehmen ... globale Bewusstsein für die Gewinnung von Quellplasma zu ... Retten und Verbessern von Leben zu würdigen ...
(Date:9/14/2014)... (PRWEB) September 15, 2014 UMBC’s ... held on Tuesday, October 21, 2014, from 12:00 to ... of the program’s innovative curriculum and practice-oriented instruction, designed ... graduate degree can help advance their career in the ... RSVP online . , About UMBC’s Biotechnology Graduate ...
(Date:9/12/2014)... Arthur Kay , the 23-year-old British founder of environmentally ... Challenge 2014. The jury, chaired by Ellen MacArthur ... final in Amsterdam to realize ... uses a patented process to upcycle waste coffee grounds ... used for powering buildings and transport systems. Bio-bean is ...
Breaking Biology Technology:Safe storage and transport of Ebola, Mers-CoV, and other viruses: Groundbreaking viral inactivation solution capable of preserving nucleic acids 2Safe storage and transport of Ebola, Mers-CoV, and other viruses: Groundbreaking viral inactivation solution capable of preserving nucleic acids 3International Plasma Awareness Week feiert Spender und rückt seltene Krankheiten in den Mittelpunkt 2International Plasma Awareness Week feiert Spender und rückt seltene Krankheiten in den Mittelpunkt 3UMBC Biotechnology Graduate Programs’ Virtual Info Session, October 21, 2014 2Green Startup Bio-Bean Wins $680,000 in Postcode Lottery Green Challenge 2Green Startup Bio-Bean Wins $680,000 in Postcode Lottery Green Challenge 3
... (Nasdaq: ONXX ) today announced that it ... on Thursday, June 26, at,10:45 a.m. Eastern Time. ... presentation on our website at:, http://www.onyx-pharm.com/wt/page/event_calendar ... on 15 minutes early in order to,register and ...
... in London on Friday, June 20, 2008, NEW ... of the,leading plaintiffs, litigation law firms in America, filed ... a New York City Fire,Department Emergency Medical Technician whose ... EMT Ernest Armstead, was one,of the many brave responders ...
... Calif., June 19 The,Fifth Annual Healthcare Unbound ... Innovation (TCBI), will feature the coming together of,consumer ... help manage,diseases. The Conference will take place at ... will include a diverse representation of the many,business ...
Cached Biology Technology:Weitz & Luxenberg Files Seroquel Diabetes Lawsuit Against AstraZeneca 2Fifth Annual Healthcare Unbound Conference to Focus on Remote Monitoring, Home Telehealth & eHealth for Disease Management & Wellness Promotion 2Fifth Annual Healthcare Unbound Conference to Focus on Remote Monitoring, Home Telehealth & eHealth for Disease Management & Wellness Promotion 3
(Date:9/15/2014)... the subsequent rapid decrease in the water level of ... square kilometres of new, fertile land in eastern Finland. ... researchers has studied the role that the decrease in ... and humans. After dramatic shifts in the waterways, human ... rise to a new, innovative culture. This stemmed from ...
(Date:9/15/2014)... weighing as much as 170 tons, the blue whale is ... heaviest living thing ever seen on Earth. So there,s no ... fish larvae, which measure millimeters in length and tip the ... Not so fast, says L. Mahadevan, the Lola England de ... and of Physics. , Using simple hydrodynamics, a team ...
(Date:9/15/2014)... cardiovascular disease (CVD) claims 17 million lives each year, ... 9.4 million. 1 New research presented by international ... Montpellier, France on September 15, 2014, suggests that milk ... , At the Milk and Dairy Products in ... risk for hypertension and CVD was examined by Dr. ...
Breaking Biology News(10 mins):The creation of the Vuoksi River preceded a significant cultural shift 2The science behind swimming 2The science behind swimming 3Dairy consumption linked to lower blood pressure and cardiovascular disease risk 2
... research into cheetah cub survival has refuted the theory that ... cannot coexist in conservation areas. The study, published in the ... Kgalagadi Transfrontier Park were seven times more likely to survive ... found to be the cubs, main predatory threat. Previously, ...
... MA -- Researchers at MIT and Brigham and Women,s ... of intestinal stem cells, then stimulate them to develop ... intestinal cells. Using these cells, scientists could develop and ... colitis. The small intestine, like most other body ...
... approach to mapping how proteins interact with each other, ... aid in the design of new drugs for diseases ... artificial amino acids, the Salk scientists determine the detailed ... the molecule that turns it on. The switch--corticotrophin releasing ...
Cached Biology News:Researchers unlock a new means of growing intestinal stem cells 2Researchers unlock a new means of growing intestinal stem cells 3Salk scientists crack riddle of important drug target 2Salk scientists crack riddle of important drug target 3
... Rabbit polyclonal to Dideoxycytidine Dideoxycytidine is ... be effective in inhibiting retroviral activity. ... BSA. Specificity: The specificity of ... ratio of the moles of ddC to moles ...
The Holten Safe 2010 Class II Biological Safety Cabinets provide the most ergonomical working condition of comfort while incorporating the latest technology for safety, efficiency and performance....
...
... The Holten MaxiSafe 2010 Class ... most ergonomical working condition of comfort ... safety, efficiency and performance.,Refined operator, environment ... of both exhausted and recirculated air.,Bottom ...
Biology Products: